Towa Pharmaceutical Co., Ltd. (4553) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Towa Pharmaceutical Co., Ltd. (4553:JPX), powered by AI.

Current Price
¥3,915
P/E Ratio
10.2
Market Cap
192.7B
Sector
Healthcare
What is the Towa Pharmaceutical Co., Ltd. stock price forecast?

Towa Pharmaceutical Co., Ltd. is currently trading at ¥3,915. View real-time AI analysis on Alpha Lenz.

What is Towa Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Towa Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Towa Pharmaceutical Co., Ltd.'s P/E ratio?

Towa Pharmaceutical Co., Ltd.'s P/E ratio is 10.2.

Towa Pharmaceutical Co., Ltd.

JPX · 4553
¥3,915+160(+4.26%)Market closedJPX regular session 09:00–15:00 JST
Ask about Towa Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Towa Pharmaceutical Co., Ltd. trades at a P/E of 10.2 (undervalued) with solid ROE of 11.6%. 3Y revenue CAGR of 16.2% highlights clear growth momentum.

Ask for details

Company Overview

Towa Pharmaceutical Co., Ltd. is a notable entity within the pharmaceutical industry, primarily focused on the research, development, manufacture, and distribution of generic medicines. These cost-effective alternatives to branded products play a critical role in healthcare by making treatments more accessible and affordable to patients worldwide. Based in Japan, Towa Pharmaceutical Co., Ltd. operates in domestic and international markets, delivering a wide range of pharmaceuticals that cover various therapeutic areas including cardiology, endocrinology, and infectious diseases. The company is particularly significant in the generics sector, where it leverages extensive manufacturing capabilities and a commitment to quality assurance, ensuring that its products meet stringent regulatory standards. Towa's impact on the market is underscored by its contribution to reducing healthcare costs and its involvement in collaborations with medical professionals to enhance patient outcomes. By expanding the availability of essential medications, Towa Pharmaceutical Co., Ltd. serves as a vital player in addressing global health challenges.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees4,788

Company Statistics

FY 2025

Profile

¥192,710,041,650Market Cap
¥259,594,000,000Revenue
0.00Shares Out
4,788Employees

Margins

36.49%Gross
17.96%EBITDA
8.95%Operating
10.14%Pre-Tax
7.31%Net

Valuation

10.15P/E
1.12P/B
0.74EV/Sales
8.11EV/EBITDA
-24.64P/FCF

Growth (CAGR)

16.16%Rev 3Yr
18.65%Rev 5Yr
6.57%Op Inc 3Yr
7.56%Op Inc 5Yr
6.06%Net Inc 3Yr
5.53%Net Inc 5Yr

Returns

4.21%ROA
11.59%ROE
6.20%ROIC

Financial Health

¥45,471,000,000Cash & Cash Equivalents
¥253,728,000,000Net Debt
174.33%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Towa Pharmaceutical Co., Ltd. (ticker: 4553) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 4,788 employees. Market cap is $192.7B.

The current price is 3,915 with a P/E ratio of 10.15x and P/B of 1.12x.

ROE is 11.59% and operating margin is 8.95%. Annual revenue is $259.6B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Towa Pharmaceutical Co., Ltd. (4553) Stock Forecast 2026 ¥3,915 — Price, Financials & Analyst Targets | Alpha Lenz